Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;29(10):951-960.
doi: 10.1007/s11655-022-3591-y. Epub 2023 Jan 6.

Potential Medicinal Value of Rhein for Diabetic Kidney Disease

Affiliations
Review

Potential Medicinal Value of Rhein for Diabetic Kidney Disease

Xi Mao et al. Chin J Integr Med. 2023 Oct.

Abstract

Diabetic kidney disease (DKD) is the primary cause of mortality among diabetic patients. With the increasing prevalence of diabetes, it has become a major concern around the world. The therapeutic effect of clinical use of drugs is far from expected, and therapy choices to slow the progression of DKD remain restricted. Therefore, research on new drugs and treatments for DKD has been a hot topic in the medical field. It has been found that rhein has the potential to target the pathogenesis of DKD and has a wide range of pharmacological effects on DKD, such as anti-nephritis, decreasing blood glucose, controlling blood lipids and renal protection. In recent years, the medical value of rhein in the treatment of diabetes, DKD and renal disease has gradually attracted worldwide attention, especially its potential in the treatment of DKD. Currently, DKD can only be treated with medications from a single symptom and are accompanied by adverse effects, while rhein improves DKD with a multi-pathway and multi-target approach. Therefore, this paper reviews the therapeutic effects of rhein on DKD, and proposes solutions to the limitations of rhein itself, in order to provide valuable references for the clinical application of rhein in DKD and the development of new drugs.

Keywords: bioavailability; diabetic kidney disease; rhein; rhein derivatives; toxicity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int 2020;97:1117–1129. - PubMed
    1. Conway BN, May ME. Mortality experience of a low-income population with young-onset diabetes. Diabetes Care 2012;35:542–548. - PubMed - PMC
    1. Gu HF. Genetic and epigenetic studies in diabetic kidney disease. Front Genet 2019;10:507. - PubMed - PMC
    1. Ram C, Jha AK, Ghosh A, et al. Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: preclinical evidences with therapeutic approaches. Eur J Pharmacol 2020;885:173503. - PubMed
    1. Brunskill NJ. C-peptide and diabetic kidney disease. J Intern Med 2017;281:41–51. - PubMed

LinkOut - more resources